Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: M. Ramle who wrote (3714)	9/20/1999 8:05:00 AM
From: BMcV	Respond to of 10280

build-out continues: James O'Shea Former Zeneca Executive Joins Sepracor As President James O'Shea Former Zeneca Executive Joins Sepracor As President and Chief Operating Officer MARBOROUGH, Mass., Sept. 20 /PRNewswire/ -- Sepracor Inc. (Nasdaq: SEPR) today announced the appointment of James O'Shea to the newly created position of President and Chief Operating Officer. Mr. O'Shea was previously Senior Vice President of Sales, Marketing and Medical Affairs for Zeneca, Inc., the $2.2 billion U.S. unit of the former Zeneca Group plc, which merged with Astra AB in 1999 to form AstraZeneca plc. At Zeneca, Mr. O'Shea was responsible for all commercial and medical operations of the U.S. subsidiary. "We are pleased to have Jim as a key member of the Sepracor management team," said Timothy J. Barberich, Chief Executive Officer of Sepracor. "Jim brings with him a depth of experience in building and leading effective commercial organizations." Throughout his 23 years of global pharmaceutical management experience, Mr. O'Shea was instrumental in growing Zeneca's U.S. business to over $2 billion in revenues. Over the past several years he led the launch of ten successful pharmaceutical products, which are leaders in a number of therapeutic categories, including respiratory therapy, central nervous system disorders, women's health, and oncology. "I am excited about the prospect of Sepracor becoming a major player as a fully integrated pharmaceutical company. The Company's chemistry-based approach for discovery of both improved and new chemical entities, has produced a robust near-term pipeline which can lead to a very large pharmaceutical business," said James O'Shea.